Methods for treatment with bucindolol based on genetic targeting
First Claim
Patent Images
1. A method for treating a human patient for heart failure, cardiac arrhythmia, or hypertension with bucindolol comprising:
- administering bucindolol to the patient if the patient is determined to be homozygous for Arg389 in the β
1 andrenergic receptor (AR) gene based on a test of a biological sample from the patient.
6 Assignments
0 Petitions
Accused Products
Abstract
The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor (AR).
-
Citations
22 Claims
-
1. A method for treating a human patient for heart failure, cardiac arrhythmia, or hypertension with bucindolol comprising:
- administering bucindolol to the patient if the patient is determined to be homozygous for Arg389 in the β
1 andrenergic receptor (AR) gene based on a test of a biological sample from the patient. - View Dependent Claims (2, 3, 4, 5, 6)
- administering bucindolol to the patient if the patient is determined to be homozygous for Arg389 in the β
-
7. A method for administering bucindolol to a human patient with symptoms of or a diagnosis of heart failure, cardiac arrhythmia, or hypertension comprising:
- administering bucindolol to the patient after bucindolol is prescribed for the patient based on test results indicating that the patient'"'"'s genotype is homozygous for Arg389 in the β
1 adrenergic receptor (AR) gene. - View Dependent Claims (8, 9, 10, 11, 12)
- administering bucindolol to the patient after bucindolol is prescribed for the patient based on test results indicating that the patient'"'"'s genotype is homozygous for Arg389 in the β
-
13. A method for treating a human patient for heart failure, cardiac arrhythmia, or hypertension with bucindolol comprising:
-
a) obtaining results from a test that determines whether the patient'"'"'s genotype is homozygous for Arg389 in the β
1 adrenergic receptor (AR) gene; and
,b) then treating the patient with bucindolol if the test indicates that the patient'"'"'s genotype is homozygous for Arg389 in the β
1 AR gene. - View Dependent Claims (14, 15, 16, 17)
-
-
18. A method for treating heart failure or cardiac arrhythmia comprising administering bucindolol to a heart failure or cardiac arrhythmia human patient who has been determined to be homozygous for Arg389 in the β
- 1 andrenergic receptor (AR) gene based on a test of a biological sample from the patient.
- View Dependent Claims (19, 20, 21, 22)
Specification